IO Biotech Q2 net loss $20.7M; cash runway into Q4 2025; Phase 3 interim analysis expected Q3 2024

IO Biotech, Inc.

Net loss of $20.7M for Q2 2024 vs $21.2M in Q2 2023; R&D expenses $15.8M.
Cash and equivalents $100.7M at June 30, 2024, down from $143.2M at year-end 2023.
Phase 3 trial (IOB-013) interim analysis for ORR expected Q3 2024; primary PFS endpoint in H1 2025.
Potential BLA submission in Q4 2024 if interim analysis supports accelerated approval.
Completed enrollment in Phase 2 basket trial (IOB-022) for NSCLC and SCCHN; data to be presented at ESMO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.